New drug cocktail aims to boost myeloma remission before transplant

NCT ID NCT05199311

Terminated Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests a combination of three drugs—carfilzomib, iberdomide, and dexamethasone—in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this mix is safe and effective at shrinking the cancer before transplant. About 66 participants will receive the drugs in cycles, and researchers will track side effects and remission rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib, iberdomide, and dexamethasone
What this could lead to: If successful, this combination could become a new initial treatment option for multiple myeloma patients before a stem cell transplant, potentially improving remission rates.
What could go wrong: This is an early-phase trial with only 66 participants, so results may not apply broadly. The drugs can cause serious side effects like heart or lung problems, and the combination may not prove more effective than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.